Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485510 | 0.88 | CCR6 (0.35) | CCR6PAX8PTGDR2 | |
| SCHEMBL13485484 | 0.81 | CCR6 (0.40) | CCR6PAX8PTGDR2PDCD1CD274 | |
| SCHEMBL13485512 | 0.74 | EGFR (0.39) | — | |
| SCHEMBL13485511 | 0.73 | EGFR (0.38) | — | |
| SCHEMBL15127675 | 0.72 | CCR6 (0.43) | CCR6PAX8PTGDR2ALDH1A1 | |
| SCHEMBL19272032 | 0.72 | CCR6 (0.43) | CCR6PAX8PTGDR2ALDH1A1 | |
| SCHEMBL24108145 | 0.71 | CCR6 (0.45) | CCR6PAX8PDCD1CD274ALDH1A1 | |
| SCHEMBL13485488 | 0.68 | CCR6 (0.43) | CCR6PAX8PTGDR2ALDH1A1 | |
| SCHEMBL13485507 | 0.68 | MAPT (0.36) | ALDH1A1 | |
| SCHEMBL13485433 | 0.68 | CCR6 (0.44) | CCR6PAX8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044084-B1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008006884-A2 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | NR4A3, NR4A1, NR5A2 | CCR6 1679/4885PAX8 549/4885PTGDR2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.